Sol Epstein

Summary

Publications

  1. ncbi Transplantation osteoporosis
    Sol Epstein
    Division of Endocrinology Mount Sinai School of Medicine, New York, USA
    Endokrynol Pol 62:472-85. 2011
  2. ncbi Is cortical bone hip? What determines cortical bone properties?
    Sol Epstein
    Medicine and Geriatrics, Mount Sinai School of Medicine, New York, USA
    Bone 41:S3-8. 2007
  3. ncbi Modern advances in the understanding of bone structure
    Sol Epstein
    Bone 41:S1-2. 2007
  4. ncbi Update of current therapeutic options for the treatment of postmenopausal osteoporosis
    Solomon Epstein
    Doylestown Hospital, Doylestown, Pennsylvania 18901, USA
    Clin Ther 28:151-73. 2006
  5. ncbi Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens
    Solomon Epstein
    Mount Sinai Medical Center, One Gustave Levy Place, New York, NY 10029, USA
    Curr Osteoporos Rep 4:14-20. 2006
  6. ncbi Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety
    Sol Epstein
    Mt Sinai Medical Center, NY, USA, and INSERM Research Unit 403 and Claude Bernard University, Lyon, France
    Maturitas 54:1-10. 2006
  7. ncbi Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg
    S Epstein
    Mt Sinai Medical Center, New York, USA
    Curr Med Res Opin 25:2951-60. 2009
  8. ncbi Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis
    S Epstein
    Metabolic Bone Unit, Doylestown Hospital, Doylestown, Philadelphia, PA 19073, USA
    Bone 37:433-40. 2005
  9. ncbi Disorders associated with acute rapid and severe bone loss
    Solomon Epstein
    Mount Sinai Bone Program, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Bone Miner Res 18:2083-94. 2003
  10. ncbi Disintegration/dissolution profiles of copies of Fosamax (alendronate)
    S Epstein
    Mount Sinai School of Medicine, New York, NY, USA
    Curr Med Res Opin 19:781-9. 2003

Detail Information

Publications26

  1. ncbi Transplantation osteoporosis
    Sol Epstein
    Division of Endocrinology Mount Sinai School of Medicine, New York, USA
    Endokrynol Pol 62:472-85. 2011
    ..This article provides a review of the current literature on osteoporosis after transplantation, and the treatment options for this serious illness...
  2. ncbi Is cortical bone hip? What determines cortical bone properties?
    Sol Epstein
    Medicine and Geriatrics, Mount Sinai School of Medicine, New York, USA
    Bone 41:S3-8. 2007
    ..Receptor activator of nuclear factor kappa B ligand (RANKL) plays a key role in bone destruction, and the human monoclonal antibody denosumab binds to RANKL, inhibiting its action and thus improving BMD significantly...
  3. ncbi Modern advances in the understanding of bone structure
    Sol Epstein
    Bone 41:S1-2. 2007
  4. ncbi Update of current therapeutic options for the treatment of postmenopausal osteoporosis
    Solomon Epstein
    Doylestown Hospital, Doylestown, Pennsylvania 18901, USA
    Clin Ther 28:151-73. 2006
    ..As the incidence of osteoporotic fractures continues to rise, it is important to identify the most effective therapies for reducing patients' risk of fracture...
  5. ncbi Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens
    Solomon Epstein
    Mount Sinai Medical Center, One Gustave Levy Place, New York, NY 10029, USA
    Curr Osteoporos Rep 4:14-20. 2006
    ..It is anticipated that once-monthly ibandronate may have a positive impact on patient adherence, and ultimately, on fracture protection in osteoporotic women...
  6. ncbi Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety
    Sol Epstein
    Mt Sinai Medical Center, NY, USA, and INSERM Research Unit 403 and Claude Bernard University, Lyon, France
    Maturitas 54:1-10. 2006
    ..This and other clinical studies conducted in postmenopausal women demonstrate that oral ibandronate has an excellent upper GI safety profile...
  7. ncbi Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg
    S Epstein
    Mt Sinai Medical Center, New York, USA
    Curr Med Res Opin 25:2951-60. 2009
    ..To increase compliance, bisphosphonate therapies with longer dose-free intervals, such as oral once monthly, were developed...
  8. ncbi Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis
    S Epstein
    Metabolic Bone Unit, Doylestown Hospital, Doylestown, Philadelphia, PA 19073, USA
    Bone 37:433-40. 2005
    ..Finally, the clinical evidence for ibandronate is briefly presented, demonstrating the viability of less frequent dosing, with its potential benefits for patient convenience and adherence to therapy...
  9. ncbi Disorders associated with acute rapid and severe bone loss
    Solomon Epstein
    Mount Sinai Bone Program, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Bone Miner Res 18:2083-94. 2003
    ..However, more severe forms of bone loss that result from an osteoblastic defect and reduced bone formation may benefit potentially more from newer anabolic agents, such as recombinant human parathyroid hormone (rhPTH)...
  10. ncbi Disintegration/dissolution profiles of copies of Fosamax (alendronate)
    S Epstein
    Mount Sinai School of Medicine, New York, NY, USA
    Curr Med Res Opin 19:781-9. 2003
    ..We performed a pilot study to compare the disintegration/dissolution profiles of FOSAMAX (alendronate) 70 mg tablets with those of copies of FOSAMAX that were manufactured outside the United States...
  11. ncbi Is treatment of early postmenopausal women with bisphosphonates justified?
    S Epstein
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Clin Pract 61:963-71. 2007
    ..Early postmenopausal women who are in a high-risk group should be considered candidates to receive bisphosphonate therapy...
  12. ncbi The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy
    Solomon Epstein
    Department of Medicine and Geriatrics, Mount Sinai School of Medicine, New York, NY, USA
    Mayo Clin Proc 80:379-88. 2005
    ....
  13. ncbi The problem of low levels of vitamin D and osteoporosis: use of combination therapy with alendronic acid and colecalciferol (vitamin D3)
    Sol Epstein
    Doylestown Hospital, Doylestown, Pennsylvania, USA
    Drugs Aging 23:617-25. 2006
    ....
  14. ncbi Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    Curr Med Res Opin 24:207-13. 2008
    ..To investigate whether once-monthly ibandronate 150 mg increases lumbar spine and total hip bone mineral density (BMD) to the same degree as weekly alendronate 70 mg...
  15. ncbi Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates
    Mone Zaidi
    The Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029, USA
    Ann N Y Acad Sci 1117:273-82. 2007
    ..The ibandronate story should serve as an important future paradigm for bisphosphonate development...
  16. ncbi Osteoporosis and diabetes mellitus
    Angela M Inzerillo
    Mount Sinai Bone Program, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Rev Endocr Metab Disord 5:261-8. 2004
  17. ncbi Nonsteroid immune modulators and bone disease
    Ronald Tamler
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Ann N Y Acad Sci 1068:284-96. 2006
    ..With the exception of glucocorticoids, all of the agents discussed here demand further investigation with regard to their effects on bone health in the clinical setting...
  18. ncbi Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss
    Mone Zaidi
    The Mount Sinai Bone Program, Box 1055, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA
    Curr Osteoporos Rep 7:118-26. 2009
    ....
  19. ncbi Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis
    Yuki Kawashima
    Division of Endocrinology, Diabetes and Bone Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Bone 44:648-55. 2009
    ..Further, these results emphasize the importance of evaluating diabetic bone based on morphology in addition to bone mass...
  20. ncbi Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans
    Mone Zaidi
    Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1055, New York, NY 10029, USA
    Ann N Y Acad Sci 1068:560-3. 2006
    ....
  21. ncbi Cellular and molecular consequences of calcineurin A alpha gene deletion
    Li Sun
    Mount Sinai Bone Program and Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Ann N Y Acad Sci 1116:216-26. 2007
    ..We speculate that the so-called "calcineurin inhibitors" may interact with molecules other than calcineurin. The clinical relevance of these observations is explored...
  22. ncbi Calcineurin regulates bone formation by the osteoblast
    Li Sun
    Bone Program and Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 102:17130-5. 2005
    ..Together, the gain- and loss-of-function experiments indicate that calcineurin regulates bone formation through an effect on osteoblast differentiation...
  23. ncbi Molecular cloning, expression, and function of osteoclastic calcineurin Aalpha
    Li Sun
    Mount Sinai Bone Program and Division of Endocrinology, Mount Sinai School of Medicine, New York, 10029, USA
    Am J Physiol Renal Physiol 284:F575-83. 2003
    ....
  24. ncbi Ibandronate: a clinical pharmacological and pharmacokinetic update
    Joanne Barrett
    Roche Products Ltd, 40 Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AY, United Kingdom
    J Clin Pharmacol 44:951-65. 2004
    ..The potency of ibandronate and its sequestration into bone allow ibandronate to be developed as oral and intravenous injection formulations that can be administered with convenient extended between-dose intervals...
  25. ncbi Long-term proton pump inhibitor therapy and risk of hip fracture
    Yu Xiao Yang
    Division of Gastroenterology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    JAMA 296:2947-53. 2006
    ..Proton pump inhibitors (PPIs) may interfere with calcium absorption through induction of hypochlorhydria but they also may reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps...
  26. ncbi Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus
    Josep M Campistol
    Unidad de Transplante Renal, Hospital Clinic i Provincial, Barcelona, Spain
    Transpl Int 18:1028-35. 2005
    ..In conclusion, future trials are warranted to test whether a sirolimus-based regimen conserves bone mineral density compared with a CsA-based regimen...